You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 130 No. 10, October 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Articles
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Systemic Leakage and Side Effects of Tumor Necrosis Factor {alpha} Administered Via Isolated Limb Perfusion Can Be Manipulated by Flow Rate Adjustment

Patrik Sorkin, MD; Subhi Abu-Abid, MD; Dina Lev, MD; Mordechai Gutman, MD; Dan Aderka, MD; Pinhas Halpern, MD; Aric Setton, MD; Nahman Kudlik, MSc; Jack Bar-On, MSc; Valery Rudich, MD; Isaak Meller, MD; Joseph M. Klausner, MD

Arch Surg. 1995;130(10):1079-1084.


Abstract

Background
The tolerated systemic dose of recombinant tumor necrosis factor {alpha} (rTNF-{alpha}) is very limited, since its administration leads to a severe septic shock—like condition. Its implementation in isolated limb perfusion (ILP) for metastatic melanoma or advanced soft-tissue sarcoma confined to the limb facilitates doses of rTNF-{alpha} 10 times higher than the systemic tolerated dose. However, with the traditional high flow rate used in ILP, systemic leakage and side effects are not eliminated.

Objective
To determine if a lower perfusion flow rate would reduce leakage and consequently toxic effects.

Methods
Isolated limb perfusion was performed for melanoma and soft-tissue sarcoma confined to the limb using a flow rate of 869 ±122 mL/min in nine patients (group 1) and a lower rate of 286±62 mL/min in six patients (group 2).

Results
The systemic leakage rate was 12.5%±2.9% in group 1, compared with 2.3%±1.0% in group 2 (P=.003). Peak TNF-{alpha} levels were 29 000±2700 pg/mL in group 1, higher than 1580±1355 pg/mL in group 2 (P=.02). The tachycardia, hypotension, increased cardiac output, decreased systemic vascular resistance, bilirubinemia, elevation of liver enzyme levels, hypocholestrolemia, thrombocytopenia, and prolongation of prothrombin and partial thromboplastin times all observed in group 1 were significantly attenuated or eliminated in group 2. The limb Po2, Pco2, pH, and viability remained similar in both groups. Also, the tumor response rate remained high and was unaffected by the decrease in flow rate.

Conclusions
Decreasing perfusion flow rate during ILP results in diminished leakage of TNF-{alpha} Consequently, the systemic hemodynamic, metabolic, and hematologic toxic effects are virtually abolished.

(Arch Surg. 1995;130:1079-1084)



Author Affiliations

From the Departments of Intensive Care and Anesthesiology (Drs Sorkin, Halpern, Setton, and Rudich), Surgery B and C (Drs Abu-Abid, Lev, Gutman, Aderka, and Klausner and Mr Kudlik), and Nuclear Medicine (Mr Bar-On), Ichilov Hospital, Tel Aviv (Israel) Sourasky Medical Center; and Sackler Faculty of Medicine, Tel Aviv University, and the National Unit of Orthopedic Oncology, Soroka Medical Center, Beersheba, Israel (Dr Meller).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Systemic Leakage and Side Effects of Tumor Necrosis Factor {alpha} Administered via Isolated Limb Perfusion Can Be Manipulated by Flow Rate Adjustment
Allen
Arch Surg 1996;131:220-220.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.